ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31

Zai Lab Ltd

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$24.06+0.87 (+3.75%)

Close on Oct 19, 2026

Market cap: $26.87B
P/E (TTM): –
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$460.16MFY2025, +221.7% a year since FY2018

Where these numbers come from

Parsed from the XBRL in Zai Lab's annual and quarterly filings with the SEC
Per-share figures adjusted for the 10-for-1 split on Mar 30, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ZLAB.

Revenue growth5.1% · median 76.1%

Operating margin-58.7% · median -71.4%

Net margin-41.9% · median -51.7%

Company	Revenue	Growth
ARQT	$463.98M	+76.1%
ZLAB	$449.61M	+5.1%
SNDX	$252.25M	+222.7%
HCM	$204.89M	-4.3%
AAPG	–	–
PHAR	–	–

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 1,784
Held by institutions: 10.1%
Auditor: KPMG LLP
SEC CIK: 1704292

Advertisement
300 × 250